Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents
- 27 January 2015
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 45 (12), 1220-1227
- https://doi.org/10.1111/hepr.12496
Abstract
Aim The purpose of this multicenter cooperative study was to elucidate the clinical features of hepatitis B virus (HBV) reactivation by chemotherapeutic agents and the patient outcomes after HBV reactivation by a retrospective review of accumulated patients’ medical records. Methods Records of a total of 27 patients (hematological malignancy, 14 patients; solid tumor, 13 patients) from 11 institutions who were diagnosed between June 2005 and October 2010 as having HBV reactivation following chemotherapy were reviewed. Results Of the 27 patients with reactivation, 16 patients were hepatitis B surface antigen (HBsAg) positive and 11 were HBsAg negative prior to the commencement of chemotherapy. Of the 11 patients who were HBsAg negative prior to the chemotherapy, 10 had hematological malignancies and one had a solid tumor. Of the 14 patients with hematological malignancies with HBV reactivation enrolled in the study, the reactivation occurred more than 12 months after the completion of chemotherapy in five patients (36%); on the other hand, none of the patients (0%) with solid tumors developed HBV reactivation more than 12 months after the completion of chemotherapy. Of the 24 patients who had acute liver dysfunction at the diagnosis of HBV reactivation, nine (38%) had severe hepatitis and seven (29%) died of liver failure. Conclusion Most of the patients with HBV reactivation who were HBsAg negative prior to the chemotherapy had underlying hematological malignancies. Furthermore, patients with hematological malignancies often developed late‐onset HBV reactivation. The prognosis of patients who develop acute liver dysfunction as a complication of HBV reactivation is extremely dismal.Keywords
Funding Information
- National Cancer Center Research and Development Fund (23-A-30)
This publication has 17 references indexed in Scilit:
- Characteristic Pattern of Reactivation of Hepatitis B Virus during Chemotherapy for Solid CancersDigestive Diseases, 2012
- Reactivation of Hepatitis B Virus in Patients Receiving ChemotherapyJapanese Journal of Clinical Oncology, 2012
- Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular CarcinomaCase Reports in Oncology, 2012
- Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapyAsia-Pacific Journal of Clinical Oncology, 2012
- Reactivation of Hepatitis B Virus After Glioblastoma Treatment With Temozolomide -Case Report-Neurologia medico-chirurgica, 2011
- Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancerBreast Cancer, 2010
- Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphomaInternational Journal of Hematology, 2009
- Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic ChemotherapyGastroenterology, 2006
- Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphomaHepatology, 2003
- Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving RituximabNew England Journal of Medicine, 2001